MS-1020 is a novel small molecule that selectively inhibits JAK3 activity

British Journal of Haematology

Volumn 148, Issue 1, 2010, Pages 132-143

  Kim, Byung Hak ^a   Oh, Sei Ryang ^b   Yin, Chang Hong ^a   Lee, Sangku ^b   Kim, Eun Ah ^b   Kim, Min Seok ^b   Sandoval, Claudio ^a   Jayabose, Somasundaram ^a   Bach, Erika A ^c   Lee, Hyeong Kyu ^b   Baeg, Gyeong Hun ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Cell based high throughput screening; Janus kinase signal transducer and activator of transcription; Plant extracts; Small molecule inhibitor

Indexed keywords

INTERLEUKIN 2; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; MS 1020; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NB(4 COUMAROYL)SEROTONIN; NB(4 FERULOYL)SEROTONIN; NB(ALPHA HYDROXYNAPHTHOYL)SEROTONIN; PLANT EXTRACT; PROLACTIN; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CATALYSIS; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DROSOPHILA; DRUG ACTIVITY; DRUG BINDING; DRUG ISOLATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; PEAR; PLANT ROOT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PYRUS COMMUNIS; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DROSOPHILA; DRUG SCREENING ASSAYS, ANTITUMOR; HODGKIN DISEASE; HUMANS; INTERLEUKIN-2; JANUS KINASE 3; NAPHTHOLS; PLANT EXTRACTS; PROTEIN KINASE INHIBITORS; RATS; SEROTONIN; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 72249115144     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07925.x     Document Type: Article

References (68)

1. Arbouzova, N.I. Zeidler, M.P. (2006) JAK/STAT signalling in Drosophila: insights into conserved regulatory and cellular functions. Development, 133, 2605 2616.
2. Bach, E.A., Vincent, S., Zeidler, M.P. Perrimon, N. (2003) A sensitized genetic screen to identify novel regulators and components of the Drosophila janus kinase/signal transducer and activator of transcription pathway. Genetics, 165, 1149 1166.
3. Baeg, G.H., Zhou, R. Perrimon, N. (2005) Genome-wide RNAi analysis of JAK/STAT signaling components in Drosophila. Genes & Development, 19, 1861 1870.
4. Battle, T.E. Frank, D.A. (2002) The role of STATs in apoptosis. Current Molecular Medicine, 2, 381 392.
5. Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., Scott, M.A., Erber, W.N. Green, A.R. Cancer Genome Project 2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 365, 1054 1061.
6. Changelian, P.S., Flanagan, M.E., Ball, D.J., Kent, C.R., Magnuson, K.S., Martin, W.H., Rizzuti, B.J., Sawyer, P.S., Perry, B.D., Brissette, W.H., McCurdy, S.P., Kudlacz, E.M., Conklyn, M.J., Elliott, E.A., Koslov, E.R., Fisher, M.B., Strelevitz, T.J., Yoon, K., Whipple, D.A., Sun, J., Munchhof, M.J., Doty, J.L., Casavant, J.M., Blumenkopf, T.A., Hines, M., Brown, M.F., Lillie, B.M., Subramanyam, C., Shang-Poa, C., Milici, A.J., Beckius, G.E., Moyer, J.D., Su, C., Woodworth, T.G., Gaweco, A.S., Beals, C.R., Littman, B.H., Fisher, D.A., Smith, J.F., Zagouras, P., Magna, H.A., Saltarelli, M.J., Johnson, K.S., Nelms, L.F., Des Etages, S.G., Hayes, L.S., Kawabata, T.T., Finco-Kent, D., Baker, D.L., Larson, M., Si, M.S., Paniagua, R., Higgins, J., Holm, B., Reitz, B., Zhou, Y.J., Morris, R.E., O'Shea, J.J. Borie, D.C. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science, 302, 875 878.
7. Chilton, B.S. Hewetson, A. (2005) Prolactin and growth hormone signaling. Current Topics in Developmental Biology, 68, 1 23.
8. Darnell, J.E. (2005) Validating Stat3 in cancer therapy. Nature Medicine, 11, 595 596.
9. Decker, P., Isenberg, D. Muller, S. (2000) Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. The Journal of Biological Chemistry, 275, 9043 9046.
10. Diaz, N., Minton, S., Cox, C., Bowman, T., Gritsko, T., Garcia, R., Eweis, I., Wloch, M., Livingston, S., Seijo, E., Cantor, A., Lee, J.H., Beam, C.A., Sullivan, D., Jove, R. Muro-Cacho, C.A. (2006) Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clinical Cancer Research, 12, 20 28.
11. Duke, J.A. (2000) Handbook of Edible Weeds: Herbal Reference Library. Taylor & Francis LLC, CRC Press, Boca Raton, FL, USA, 144 145.
12. Eisenbrand, G., Hippe, F., Jakobs, S. Muehlbeyer, S. (2004) Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. Journal of Cancer Research and Clinical Oncology, 130, 627 635.
13. Epling-Burnette, P.K., Liu, J.H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.M., Yang-Yen, H.F., Karras, J., Jove, R. Loughran, Jr., T.P. (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. The Journal of Clinical Investigation, 107, 351 362.
14. Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F., Martinelli, S., Fragale, A., Sanchez, M., Tavolaro, S., Messina, M., Cazzaniga, G., Camera, A., Pizzolo, G., Tornesello, A., Vignetti, M., Battistini, A., Cavé, H., Gelb, B.D., Renauld, J.C., Biondi, A., Constantinescu, S.N., Foà, R. Tartaglia, M. (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. The Journal of Experimental Medicine, 205, 751 758.
15. Grover, J.K. Yadav, S.P. (2004) Pharmacological actions and potential uses of Momordica charantia: a review. Journal of Ethnopharmacology, 93, 123 132.
16. Hou, S.X., Zheng, Z., Chen, X. Perrimon, N. (2002) The Jak/STAT pathway in model organisms: emerging roles in cell movement. Developmental Cell, 3, 765 778.
17. James, C., Ugo, V., Le Couédic, J.P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J.L., Constantinescu, S.N., Casadevall, N. Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Natrure, 434, 1144 1148. (Pubitemid 40663494)
18. Jones, A.V., Chase, A., Silver, R.T., Oscier, D., Zoi, K., Wang, Y.L., Cario, H., Pahl, H.L., Collins, A., Reiter, A., Grand, F. Cross, N.C. (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nature Genetics, 41, 446 449.
19. Kang, K., Park, S., Kim, Y.S., Lee, S. Back, K. (2009) Biosynthesis and biotechnological production of serotonin derivatives. Applied Microbiology and Biotechnology, 83, 27 34.
20. Kawashima, S., Hayashi, M., Takii, T., Kimura, H., Zhang, H.L., Nagatsu, A., Sakakibara, J., Murata, K., Oomoto, Y. Onozaki, K. (1998) Serotonin derivative, N-(p-coumaroyl) serotonin, inhibits the production of TNF-alpha, IL-1alpha, IL-1beta, and IL-6 by endotoxin-stimulated human blood monocytes. Journal of Interferon & Cytokine Research, 18, 423 428.
21. Kilpivaara, O., Mukherjee, S., Schram, A.M., Wadleigh, M., Mullally, A., Ebert, B.L., Bass, A., Marubayashi, S., Heguy, A., Garcia-Manero, G., Kantarjian, H., Offit, K., Stone, R.M., Gilliland, D.G., Klein, R.J. Levine, R.L. (2009) A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nature Genetics, 41, 455 459.
22. Kim, B.H., Yin, C.H., Guo, Q., Bach, E.A., Lee, H., Sandoval, C., Jayabose, S., Ulaczyk-Lesanko, A., Hall, D.G. Baeg, G.H. (2008) A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells. Molecular Cancer Therapeutics, 7, 2672 2680.
23. Kirken, R.A., Rui, H., Malabarba, M.G. Farrar, W.L. (1994) Identification of interleukin-2 receptor-associated tyrosine kinase p116 as novel leukocyte-specific Janus kinase. The Journal of Biological Chemistry, 269, 19136 19141.
24. Kiyoi, H., Yamaji, S., Kojima, S. Naoe, T. (2007) JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia, 21, 574 576.
25. Klampfer, L. (2006) Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Current Cancer Drug Targets, 6, 107 121.
26. Kota, J., Caceres, N. Constantinescu, S.N. (2008) Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia, 22, 1828 1840.
27. Levine, R.L. (2009) Janus kinase mutations. Seminars in Oncology, 36, S6 S11.
28. Levine, R.L., Loriaux, M., Huntly, B.J., Loh, M.L., Beran, M., Stoffregen, E., Berger, R., Clark, J.J., Willis, S.G., Nguyen, K.T., Flores, N.J., Estey, E., Gattermann, N., Armstrong, S., Look, A.T., Griffin, J.D., Bernard, O.A., Heinrich, M.C., Gilliland, D.G., Druker, B. Deininger, M.W. (2005) The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood, 106, 3377 3379.
29. Levy, D.E. Darnell, Jr., J.E. (2002) Stats: transcriptional control and biological impact. Nature Reviews. Molecular Cell Biology, 3, 651 662.
30. Mahboubi, K., Li, F., Plescia, J., Kirkiles-Smith, N.C., Mesri, M., Du, Y., Carroll, J.M., Elias, J.A., Altieri, D.C. Pober, J.S. (2001) Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Laboratory Investigation, 81, 327 334.
31. Malinge, S., Ragu, C., Della-Valle, V., Pisani, D., Constantinescu, S.N., Perez, C., Villeval, J.L., Reinhardt, D., Landman-Parker, J., Michaux, L., Dastugue, N., Baruchel, A., Vainchenker, W., Bourquin, J.P., Penard-Lacronique, V. Bernard, O.A. (2008) Activating mutations in human acute megakaryoblastic leukemia. Blood, 112, 4220 4226.
32. Meraz, M.A., White, J.M., Sheehan, K.C., Bach, E.A., Rodig, S.J., Dighe, A.S., Kaplan, D.H., Riley, J.K., Greenlund, A.C., Campbell, D., Carver-Moore, K., DuBois, R.N., Clark, R., Aguet, M. Schreiber, R.D. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell, 84, 431 442.
33. Mullighan, C.G., Zhang, J., Harvey, R.C., Collins-Underwood, J.R., Schulman, B.A., Phillips, L.A., Tasian, S.K., Loh, M.L., Su, X., Liu, W., Devidas, M., Atlas, S.R., Chen, I.M., Clifford, R.J., Gerhard, D.S., Carroll, W.L., Reaman, G.H., Smith, M., Downing, J.R., Hunger, S.P. Willman, C.L. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 106, 9414 9418.
34. Neilson, L.M., Zhu, J., Xie, J., Malabarba, M.G., Sakamoto, K., Wagner, K.U., Kirken, R.A. Rui, H. (2007) Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Molecular Endocrinology, 21, 2218 2232.
35. Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U. Pfeffer, K. (1998) Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell, 93, 397 409.
36. Niwa, T., Etoh, H., Shimizu, A. Shimizu, Y. (2000) Cis-N-(p-Coumaroyl) serotonin from Konnyaku, Amorphophallus konjac K. Koch. Bioscience, Biotechnology, and Biochemistry, 64, 2269 2271.
37. Nosaka, T., van Deursen, J.M., Tripp, R.A., Thierfelder, W.E., Witthuhn, B.A., McMickle, A.P., Doherty, P.C., Grosveld, G.C. Ihle, J.N. (1995) Defective lymphoid development in mice lacking Jak3. Science, 270, 800 802.
38. Nybakken, K., Vokes, S.A., Lin, T.Y., McMahon, A.P. Perrimon, N. (2005) A genome-wide RNA interference screen in Drosophila melanogater cells for new components of the Hh signaling pathway. Nature Genetics, 37, 1323 1332.
39. O'Shea, J.J., Pesu, M., Borie, D.C. Changelian, P.S. (2004) A new modality for immunosuppression: targeting the JAK/STAT pathway. Nature Reviews. Drug Discovery, 3, 555 564.
40. Olcaydu, D., Harutyunyan, A., Jäger, R., Berg, T., Gisslinger, B., Pabinger, I., Gisslinger, H. Kralovics, R. (2009) A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nature Genetics, 41, 450 454.
41. Park, J.B. Schoene, N. (2002) Synthesis and characterization of N-coumaroyltyramine as a potent phytochemical which arrests human transformed cells via inhibiting protein tyrosine kinases. Biochemical and Biophysical Research Communications, 292, 1104 1110.
42. Park, S.Y., Saijo, K., Takahashi, T., Osawa, M., Arase, H., Hirayama, N., Miyake, K., Nakauchi, H., Shirasawa, T. Saito, T. (1995) Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity, 3, 771 782.
43. Parsons, S.J. Parsons, J.T. (2004) Src family kinases, key regulators of signal transduction. Oncogene, 23, 7906 7909.
44. Pesu, M., Candotti, F., Husa, M., Hofmann, S.R., Notarangelo, L.D. O'Shea, J.J. (2005) Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunological Reviews, 203, 127 142.
45. Pesu, M., Laurence, A., Kishore, N., Zwillich, S.H., Chan, G. O'Shea, J.J. (2008) Therapeutic targeting of Janus kinases. Immunological Reviews, 223, 132 142.
46. Reiterer, G. Yen, A. (2006) Inhibition of the janus kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreduplication. Cancer Research, 66, 9083 9089.
47. Roh, J.S., Han, J.Y., Kim, J.H. Hwang, J.K. (2004) Inhibitory effects of active compounds isolated from safflower (Carthamus tinctorius L.) seeds for melanogenesis. Biological & Pharmaceutical Bulletin, 27, 1976 1978.
48. Rui, H., Kirken, R.A. Farrar, W.L. (1994) Activation of receptor-associated tyrosine kinase JAK2 by prolactin. The Journal of Biological Chemistry, 269, 5364 5368.
49. Sato, T., Toki, T., Kanezaki, R., Xu, G., Terui, K., Kanegane, H., Miura, M., Adachi, S., Migita, M., Morinaga, S., Nakano, T., Endo, M., Kojima, S., Kiyoi, H., Mano, H. Ito, E. (2008) Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome. British Journal of Haematology, 141, 681 688.
50. Schindler, C., Shuai, K., Prezioso, V.R. Darnell, Jr., J.E. (1992) Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science, 257, 809 813.
51. Schindler, C., Levy, D.E. Decker, T. (2007) JAK-STAT signaling: from interferons to cytokines. The Journal of Biological Chemistry, 282, 20059 20063.
52. Shuai, K., Schindler, C., Prezioso, V.R. Darnell, Jr., J.E. (1992) Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science, 285, 1808 1812.
53. Shuai, K., Stark, G.R., Kerr, I.M. Darnell, Jr., J.E. (1993a) A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science, 261, 1744 1746.
54. Shuai, K., Ziemiecki, A., Wilks, A.F., Harpur, A.G., Sadowski, H.B., Gilman, M.Z. Darnell, Jr., J.E. (1993b) Polypeptide signalling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature, 366, 580 583.
55. Shuai, K., Horvath, C.M., Huang, L.H., Qureshi, S.A., Cowburn, D. Darnell, Jr., J.E. (1994) Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell, 76, 821 828.
56. Steelman, L.S., Pohnert, S.C., Shelton, J.G., Franklin, R.A., Bertrand, F.E. McCubrey, J.A. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 18, 189 218.
57. Stepkowski, S.M., Erwin-Cohen, R.A., Behbod, F., Wang, M.E., Qu, X., Tejpal, N., Nagy, Z.S., Kahan, B.D. Kirken, R.A. (2002) Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood, 99, 680 689.
58. Stepkowski, S.M., Kao, J., Wang, M.E., Tejpal, N., Podder, H., Furian, L., Dimmock, J., Jha, A., Das, U., Kahan, B.D. Kirken, R.A. (2005) The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. Journal of Immunology, 175, 4236 4246.
59. Stickel, F. Schuppan, D. (2007) Herbal medicine in the treatment of liver diseases. Digestive and Liver Disease, 39, 293 304.
60. Sudbeck, E.A., Liu, X.P., Narla, R.K., Mahajan, S., Ghosh, S., Mao, C. Uckun, F.M. (1999) Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clinical Cancer Research, 5, 1569 1582. (Pubitemid 29282966)
61. Takii, T., Hayashi, M., Hiroma, H., Chiba, T., Kawashima, S., Zhang, H.L., Nagatsu, A., Sakakibara, J. Onozaki, K. (1999) Serotonin derivative, N-(p-Coumaroyl)serotonin, isolated from safflower (Carthamus tinctorius L.) oil cake augments the proliferation of normal human and mouse fibroblasts in synergy with basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). Journal of Biochemistry, 125, 910 915.
62. Thomis, D.C., Gurniak, C.B., Tivol, E., Sharpe, A.H. Berg, L.J. (1995) Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science, 270, 794 797.
63. Velazquez, L., Fellous, M., Stark, G.R. Pellegrini, S. (1992) A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell, 70, 313 322.
64. Walters, D.K., Mercher, T., Gu, T.L., O'Hare, T., Tyner, J.W., Loriaux, M., Goss, V.L., Lee, K.A., Eide, C.A., Wong, M.J., Stoffregen, E.P., McGreevey, L., Nardone, J., Moore, S.A., Crispino, J., Boggon, T.J., Heinrich, M.C., Deininger, M.W., Polakiewicz, R.D., Gilliland, D.G. Druker, B.J. (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 10, 65 75.
65. Watling, D., Guschin, D., Müller, M., Silvennoinen, O., Witthuhn, B.A., Quelle, F.W., Rogers, N.C., Schindler, C., Stark, G.R., Ihle, J.N. Kerr, I.M. (1993) Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature, 366, 166 170.
66. Yu, H. Jove, R. (2004) The STATs of cancer - new molecular targets come of age. Nature reviews. Cancer, 4, 97 105.
67. Zeidler, M.P., Bach, E.A. Perrimon, N. (2000) The roles of the Drosophila JAK/STAT pathway. Oncogene, 19, 2598 2606.
68. Zhou, L., Zuo, Z. Chow, M.S. (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Journal of Clinical Pharmacology, 45, 1345 1359.